Sandra Levy
ARTICLES BY THIS AUTHOR
- 10/14/2020
Regeneron gets FDA green light for first Ebola treatment Inmazeb
Regeneron’s Inmazeb is the first FDA-approved treatment for Ebola virus infection in adult and pediatric patients. - 10/14/2020
Tabula Rasa HealthCare, APhA kick off medication safety campaign
Tabula Rasa and the American Pharmacists Association are rolling out a campaign to educate consumers on medication safety, the risks of adverse drug events and the essential role the pharmacist can play on the patient care team. - 10/14/2020
Harmony Biosciences obtains FDA OK for new indication for Wakix
Harmony's Wakix is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. - 10/13/2020
i-SENS offers 2 new blood glucose monitoring systems
i-SENS is adding CareSens N Plus, and CareSens S Fit blood glucose monitoring systems to its blood glucose meter portfolio. - 10/13/2020
Innovation changes name to iA
Innovation’s new brand, iA, reflects on its commitment of enabling pharmacy providers and healthcare organizations to focus on increasing pharmacy services. - 10/12/2020
Strides Pharma acquires FDA OK for generic butalbital, acetaminophen and caffeine
Butalbital, acetaminophen and caffeine tablets had a market value of roughly $40 million, according to IQVIA July 2020 data. - 10/12/2020
Micro Labs USA launches 2 generics
Dorzolamide and dorzolamide-timolol have a market value of approximately $150 million, according to IQVIA. - 10/12/2020
Hy-Vee, Julie and Kirk Cousins Foundation launch charity-focused cereal
Proceeds from the sale of Cousins CinnaMINN Snaps cereal, sold at select Hy-Vee stores throughout Minnesota, will benefit the Boys & Girls Clubs of the Twin Cities. - 10/12/2020
Bonum Health partners with SingleCare to bring prescription savings to patients
Bonum Health and SingleCare are teaming up to help consumers with access and adherence to affordable prescriptions. - 10/11/2020
Mallinckrodt files for bankruptcy
Mallinckrodt and its U.S. subsidiaries, including its specialty generics-focused and specialty brands-related subsidiaries, as well as some of its international subsidiaries, have filed Chapter 11 petitions.
